Kidney Week

Abstract: SA-PO268

Consistent Kidney Benefits With Semaglutide vs. Placebo Regardless of Baseline Urine Albumin Creatinine Ratio in Subjects With Type 2 Diabetes at High Cardiovascular Risk: A Post Hoc Analysis of SUSTAIN 6

Session Information

• Diabetic Kidney Disease: Clinical - II
  November 05, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
  Abstract Time: 10:00 AM - 12:00 PM

Category: Diabetic Kidney Disease

• 602 Diabetic Kidney Disease: Clinical

Authors

• L Heerspink, Hiddo Jan, University Medical Center Groningen, Groningen, Netherlands

Hiddo Jan L Heerspink,

• Kuhlman, Anja Birk, Novo Nordisk A/S, Søborg, Denmark

Anja Birk Kuhlman,

• Mann, Johannes F., KfH Kidney Center, München, Germany

Johannes F. Mann,

• Rasmussen, Soren, Novo Nordisk A/S, Søborg, Denmark

Soren Rasmussen,

• Rossing, Peter, Steno Diabetes Center Copenhagen, Herlev, Denmark

Peter Rossing,

• Vrhnjak, Blaz, Novo Nordisk A/S, Søborg, Denmark

Blaz Vrhnjak,

• Cherney, David, University Health Network, Toronto, Ontario, Canada

David Cherney,

Background

In a previous analysis of SUSTAIN 6 and PIONEER 6 (cardiovascular [CV] outcomes trials in subjects with type 2 diabetes [T2D] at high CV risk), semaglutide reduced estimated glomerular filtration rate (eGFR) slope vs placebo, both in addition to standard of care antidiabetes medication. This was most pronounced in those with eGFR <60 mL/min/1.73 m²; it is of clinical interest to understand if this benefit is consistent across urine albumin:creatinine ratio (UACR) groups. The aim of this post hoc analysis was to investigate the effects of semaglutide on eGFR slopes in subjects with different albuminuria levels at baseline in SUSTAIN 6 (PIONEER 6 was excluded as UACR was not collected in this trial).

Methods

eGFR slope estimated by a random effect model was compared in subjects by baseline UACR: <30/≥30−≤300/>300 mg/g. To account for potential differences in baseline characteristics, a sensitivity analysis was performed. These subgroups were also compared in those with baseline eGFR ≥30−<60 or ≥60 mL/min/1.73 m².

Results

Across the three subgroups (N=3,232), baseline characteristics were similar, except for higher blood pressure and lower eGFR in subjects with UACR >300 mg/g vs other subgroups. Overall, subjects receiving semaglutide had a slower decline in eGFR at 2 years vs placebo, an effect that was consistent across the three subgroups (p-value for interaction: 0.99; Figure). Results were consistent in the sensitivity analysis and those with eGFR ≥30−<60 vs ≥60 mL/min/1.73 m².

Conclusion

Semaglutide appears to slow eGFR decline vs placebo in subjects with T2D at high CV risk regardless of baseline albuminuria status.

Estimated annual eGFR slopes according to treatment and UACR groups at baseline

Funding

• Commercial Support – Novo Nordisk A/S